Skip to main content
Equibles
CCCC logo

CCCC · C4 Therapeutics, Inc. · Metrics

Track CCCC — free

Use CCCC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CCCC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.77 -0.12 (-4.15%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$363.75M
Shares
131.32M
Volume · Nov 12 4.97M Avg daily vol (3M) 2.53M

CCCC metrics

77 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.77
Market cap
$363.75M

Price action

23 metrics
Price change (1W)
-7.4%
Price change (30D)
+4.0%
Price change (3M)
-25.9%
Price change (6M)
-21.5%
Price change (YTD)
+51.3%
Price change (1Y)
+16.5%
Trailing year
Price change (5Y)
-93.3%
52-week high
$4.67
52-week low
$1.71
Change from 52-week high
-38.1%
Change from 52-week low
+69.0%
Annualized volatility
80.8%
Annualized volatility (3M)
65.1%
Implied volatility (30D)
141.0%
IV rank (1Y)
29.3
IV percentile (1Y)
90.9
Beta
1.7
RSI (14D)
42.5
Price vs SMA 50
-9.0%
Price vs SMA 200
-10.9%
Avg volume (3M)
2.49M
Relative volume
0.9
Average dollar volume
$8.34M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
131.32M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.4×
reciprocal yield 18.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
11.8×
reciprocal yield 8.5%
P / book
1.7
reciprocal yield 60.1%
FCF yield
-21.0%
TTM · current market cap
Buyback yield
0.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
-24.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.5×
reciprocal yield 22.0%
EV / revenue historical average (5Y)
2.4×
reciprocal yield 41.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-26

Profitability

9 metrics
Gross margin
—
Operating margin
-315.9%
Trailing 12 months
Net margin
-282.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$101.95M
Net income (TTM)
−$91.09M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
-247.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.65

Growth

11 metrics
Revenue growth YoY
-24.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$32.28M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+87.5%
Year over year · more shares
Revenue CAGR (3Y)
+5.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-39.9%
Return on assets
-27.5%
Debt / equity
0.0
Current ratio
5.2
EBITDA (TTM)
−$100.50M
Free cash flow (TTM)
−$79.74M
Quick ratio
5.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$32.42M
Latest balance sheet
Cash & equivalents
$32.42M
Total assets
$331.80M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$79.63M
Capital expenditures (TTM)
$112,000
R&D (TTM)
$98.86M
SG&A (TTM)
—
Stock compensation (TTM)
$12.69M
R&D / revenue
306.3%
Stock compensation / revenue
39.3%

Ownership (13F)

9 metrics
13F filers
148
13F filer change QoQ
+25
Institutional ownership
90.4%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+31.5%
Holder tenure
11.8
Price vs estimated holder cost
+18.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.6%

Short interest

3 metrics
Short interest
35.5%
Latest settlement · 15.1 days to cover
Days to cover
15.1d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1662579 CUSIP 12529R107 13F (30d) 75 filings 62 filers Visit website Investor relations